Search Results 1701-1710 of 18742 for Activation

  1. Clinical trials - Oncology (Medical)

    Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements ...

  2. Publications - Omar F. Abou Ezzeddine, M.D., M.S. - Mayo Clinic

    Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail. 2015 Feb; 3 (2):97-107 Epub 2014 Oct 31

  3. Publications - Stacy D. D'Andre, M.D. - Mayo Clinic

    Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res. 2014 Jul 1; 74 (13):3512-24 Epub 2014 ...

  4. Clinical trials - Oncology (Medical)

    ... activation and exhaustion. Phase 2 Trial Of Voyager V1 In Combination With Cemiplimab In Cancer Patients. Rochester, Minn., Jacksonville, Fla., Scottsdale ...

  5. Clinical trials - Oncology (Medical)

    We present here a CAR design that allows PD-1 to recognize PD-L1 on the tumor; however, the intracellular CAR design is one that results in T cell activation as ...

  6. A Study to Investigate the Effectiveness and Safety of Pf-04965842 in Subjects Aged 12 Years and Over, With Moderate to Severe Atopic Dermatitis with the Option of Rescue Treatment in Flaring Subjects - Mayo Clinic

    ... activated cell sorting (FACS) analysis. Within 12 weeks of first dose of investigational product: Other biologics: within 12 weeks of first dose of ...

  7. Clinical trials - Oncology (Medical)

    ... activation and exhaustion. A Study to Evaluate the Incidence and Psychological Impact of Vaginal Cuff Dehiscence After Different Types of Hysterectomy.

  8. A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies - Mayo Clinic

    Prothrombin time (PT) (or International Normalized Ratio [INR]) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN or within the intended ...

  9. RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC - Mayo Clinic

    collection). 10. Prothrombin time ≤ 1.5 × ULN (or international normalization ratio [INR] ≤ 1.3) and partial thromboplastin time (PTT) or activated partial ...

  10. Publications - Allison C. Rosenthal, D.O. - Mayo Clinic

    Refractory marginal zone lymphoma uncovers activated phosphoinositide 3-kinase delta syndrome type 1 (APDS1). J Allergy Clin Immunol Glob. 2025 Aug; 4 (3): ...